The role of REV-ERBα in immune responses is well established [reviewed in (36)], and recently synthetic REV-ERBα agonists are being used in vivo to investigate a direct circadian modulation in IMIDs such as in Rheumatoid Arthritis (RA) and colitis. Here, NR1D1 is linked to rheumatoid arthritis.